Nimit Rajesh Ghatalia files substantial acquisition disclosure under SEBI Takeover Code for Aarey Drugs

M&A / JV 1 Jul 2026 · Announced· ✓ Verified

Nimit Rajesh Ghatalia submitted a Regulation 31(4) disclosure under SEBI's Substantial Acquisition of Shares and Takeovers (SAST) Regulations, 2011, to the National Stock Exchange on or around 1 July 2026. Regulation 31(4) requires disclosure when a person acquires or agrees to acquire shares or voting rights such that the aggregate shareholding (including associates) reaches or exceeds 25% of total voting capital, or when a person (already holding 25%+) makes a further acquisition to increase shareholding by 2% or more in a 12-month period. The filing indicates either a new substantial stake entry or a material increase by an existing substantial shareholder in Aarey Drugs, a…

Why it mattersRegulation 31(4) disclosure signals crossing of 25% threshold or intent to acquire control; this precedent underscores that even non-public pharmaceutical acquisitions in India must clear SEBI Takeover Code gates before shareholding restructuring becomes effective-a critical gating item for PE and strategic pharma M&A.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals